Loading data for PHIO — first visit, this takes a few seconds.
Phio Pharmaceuticals Corp... (PHIO)
NasdaqCM: PHIO
· Precio en tiempo real · USD
1.14
+0.09 (8.57%)
Al cierre: Aug 18, 2026, 3:59 PM
1.15
+0.00%
Fuera de horario: 4:39 PM
Phio Pharmaceuticals Corp. (PHIO) Stock Price, Analysis & Data
8.57% (1D)
| Precio de compra | 0.82 |
| Capitalización de mercado | 13.36M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -12.9M |
| Beta | 0.79 |
| EPS (TTM) | -1.29 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -1.83 |
| P/B (TTM) | 0.81 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | 1.39 |
| Volumen | 515,888 |
| Volumen medio (20D) | 605,975 |
| Abierto | 1.10 |
| Anterior Cerrar | 1.05 |
| Rango del día | 1.08 - 1.16 |
| Rango de 52 semanas | 0.81 - 4.19 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de PHIO
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclin...
Industria Biotechnology
Sector Healthcare
IPO Fecha May 10, 2012
Empleados 6
Bolsa de Valores NasdaqCM
Símbolo bursátil PHIO
Sitio web https://phiopharma.com
Desempeño financiero
En 2025, los ingresos de Phio Pharmaceuticals fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -8.7M, un aumento de 21.65%.
Estados financierosSorpresa de resultados
Phio Pharmaceuticals ha publicado sus resultados trimestrales en Aug 6, 2026:
